Displaying drugs 14951 - 14975 of 15704 in total
GX-G8
GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
Investigational
Ilixadencel
Investigational
GRObeta
Investigational
TSHA-104
Investigational
XMT-2056
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
AP103
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
TLR-AD1
Investigational
Human autologous bone marrow derived osteoblastic cells
Investigational
Human glial progenitor cells
Investigational
HM15912
HM15912 is a human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment.
Investigational
LX2006
Investigational
SP-101
Investigational
OT-004
Investigational
CT-001
Investigational
AO-176
Investigational
CM-101
Investigational
4D-110
Investigational
JAG101
Investigational
BMN-331
Investigational
OptPA
Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.
Investigational
NGN-101
NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene
Investigational
TLY-012
TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL).
Investigational
GS-100
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Investigational
FBX-101
FBX-101 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene
Investigational
AAV-RPE65
AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene
Investigational
Displaying drugs 14951 - 14975 of 15704 in total